Physiologically based pharmacokinetic (PBPK) modeling of the bisphenols BPA, BPS, BPF, and BPAF with new experimental metabolic parameters: Comparing the pharmacokinetic behavior of BPA with its substitutes

Environmental Health Perspectives

Volumn 126, Issue 7, 2018, Pages

  Karrer, Cecile ^a   Roiss, Thomas ^a   von Goetz, Natalie ^a   Skledar, Darja Gramec ^b   Mašič, Lucija Peterlin ^b   Hungerbühler, Konrad ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; BISPHENOL AF; BISPHENOL F; BISPHENOL S; ENDOCRINE DISRUPTOR; ESTROGEN RECEPTOR; UNCLASSIFIED DRUG; 4,4'-HEXAFLUORISOPROPYLIDENE DIPHENOL; BENZHYDRYL DERIVATIVE; BIS(4-HYDROXYPHENYL)SULFONE; PHENOL DERIVATIVE; SULFONE;

ACCURACY; ADULT; ARTICLE; BINDING AFFINITY; BIOLOGICAL MONITORING; CALIBRATION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENTEROHEPATIC CIRCULATION; ESTROGEN ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAXIMUM REACTION VELOCITY; MONTE CARLO METHOD; PRIORITY JOURNAL; TWO-DIMENSIONAL IMAGING; UNCERTAINTY; URINARY EXCRETION; ADOLESCENT; ANALYSIS; BIOLOGICAL MODEL; COMPARATIVE STUDY; ENVIRONMENTAL EXPOSURE; PHARMACOKINETICS; POLLUTANT; YOUNG ADULT;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; ENDOCRINE DISRUPTORS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; FEMALE; HUMANS; MODELS, BIOLOGICAL; PHENOLS; SULFONES; YOUNG ADULT;

EID: 85050350598     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/EHP2739     Document Type: Article

References (99)

1. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, et al. 2007. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity per gram of liver. Curr Drug Metab 8(1):33–45, PMID: 17266522, https://doi.org/10.2174/138920007779315053.
2. Bautista-Toledo I, Ferro-García MA, Rivera-Utrilla J, Moreno-Castilla C, Vegas Fernández FJ. 2005. Bisphenol A removal from water by activated carbon. effects of carbon characteristics and solution chemistry. Environ Sci Technol 39(16):6246–6250, PMID: 16173588, https://doi.org/10.1021/es0481169.
3. Biedermann S, Tschudin P, Grob K. 2010. Transfer of bisphenol A from thermal printer paper to the skin. Anal Bioanal Chem 398(1):571–576, PMID: 20623271, https://doi.org/10.1007/s00216-010-3936-9.
4. Boucher JG, Boudreau A, Ahmed S, Atlas E. 2015. In vitro effects of bisphenol A β-D-Glucuronide (BPA-G) on adipogenesis in human and murine preadipocytes. Environ Health Perspect 123(12):1287–1293, PMID: 26018136.
5. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484, PMID: 9249929, https://doi.org/10.1177/074823379701300401.
6. Calafat AM, Ye X, Wong L-Y, Reidy JA, Needham LL. 2008. Exposure of the U.S. population to bisphenol A and 4-tertiary-Octylphenol: 2003-2004 test. Environ Health Perspect 116(1):39–44, PMID: 18197297, https://doi.org/10.1289/ehp.10753.
7. Chen D, Kannan K, Tan H, Zheng Z, Feng Y-L, Wu Y, et al. 2016. Bisphenol analogues other than BPA: environmental occurrence, human exposure, and toxicity—a review. Environ Sci Technol 50(11):5438–5453, PMID: 27143250, https://doi.org/10.1021/acs.est.5b05387.
8. Choi YJ, Lee LS. 2017. Partitioning behavior of bisphenol alternatives BPS and BPAF compared to BPA. Environ Sci Technol 51(7):3725–3732, PMID: 28274112, https://doi.org/10.1021/acs.est.6b05902.
9. Coughlin JL, Thomas PE, Buckley B. 2012. Inhibition of genistein glucuronidation by bisphenol A in human and rat liver microsomes. Drug Metab Dispos 40(3):481– 485, PMID: 22146138, https://doi.org/10.1124/dmd.111.042366.
10. Covaci A, Hond ED, Geens T, Govarts E, Koppen G, Frederiksen H, et al. 2015. Urinary BPA measurements in children and mothers from six European member states: overall results and determinants of exposure. Environ Res 141:77– 85, PMID: 25440295, https://doi.org/10.1016/j.envres.2014.08.008.
11. DeJongh J, Verhaar HJM, Hermens JLM. 1997. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 72(1):17–25, PMID: 9458186, https://doi.org/10.1007/s002040050463.
12. Demierre A-L, Peter R, Oberli A, Bourqui-Pittet M. 2012. Dermal penetration of bisphenol A in human skin contributes marginally to total exposure. Toxicol Lett 213(3):305–308, PMID: 22796587, https://doi.org/10.1016/j.toxlet.2012.07. 001.
13. Doerge DR, Twaddle NC, Vanlandingham M, Brown RP, Fisher JW. 2011. Distribution of bisphenol A into tissues of adult, neonatal, and fetal Sprague–Dawley rats. Toxicol Appl Pharmacol 255(3):261–270, PMID: 21820460, https://doi.org/10.1016/j. taap.2011.07.009.
14. Draganov DI, Markham DA, Beyer D, Waechter JM, Dimond SS, Budinsky RA, et al. 2015. Extensive metabolism and route-dependent pharmacokinetics of bisphenol A (BPA) in neonatal mice following oral or subcutaneous administration. Toxicology 333:168–178., PMID: 25929835, https://doi.org/10.1016/j.tox.2015.04. 012.
15. Dumont C, Perdu E, Sousa G, de Debrauwer L, Rahmani R, Cravedi J-P, et al. 2011. Bis(hydroxyphenyl)methane—bisphenol F—metabolism by the HepG2 human hepatoma cell line and cryopreserved human hepatocytes. Drug Chem Toxicol 34(4):445–453, PMID: 21770713, https://doi.org/10.3109/01480545.2011.585651.
16. EC (European Commission). 2011a. Commission Directive 2011/8/EU of 28 January 2011 amending Directive 2002/72/EC as regards the restriction of use of Bisphenol A in plastic infant feeding bottles.
17. EC. 2011b. Commission Regulation (EU) No 10/2011 of 14 January 2011 on Plastic Materials and Articles Intended to Come into Contact with Food.
18. Edginton AN, Schmitt W, Willmann S. 2006. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45(10):1013–1034, PMID: 16984214, https://doi.org/10.2165/00003088-200645100-00005.
19. EFSA CEF (European Food Safety Authority Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids). 2015. Scientific opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. EFSA Journal 13(1):3978, https://doi.org/10.2903/j.efsa.2015.3978.
20. EFSA Scientific Committee. 2016. Guidance on Uncertainty in EFSA Scientific Assessment-Revised Draft for Internal Testing.
21. Elsby R, Maggs JL, Ashby J, Park BK. 2001. Comparison of the modulatory effects of human and rat liver microsomal metabolism on the estrogenicity of bisphenol A: implications for extrapolation to humans. J Pharmacol Exp Ther 297(1):103–113, PMID: 11259533.
22. EU (European Union). 2008. Updated European Risk Assessment Report 4,4’-isopropylidenediphenol (Bisphenol-A).
23. U.S. FDA. 2013. FDA Regulations No Longer Authorize the Use of BPA in Infant Formula Packaging Based on Abandonment; Decision Not Based on Safety. http://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm360147.htm [accessed 14 June, 2018].
24. U.S. FDA (U.S. Food and Drug Administration). 2014. Bisphenol A (BPA): Use in Food Contact Application. http://www.fda.gov/Food/IngredientsPackagingLabeling/FoodAdditivesIngredients/ucm064437.htm [accessed 14 June, 2018].
25. Fic A, Žegura B, Gramec D, Mašič LP. 2014. Estrogenic and androgenic activities of TBBA and TBMEPH, metabolites of novel brominated flame retardants, and selected bisphenols, using the XenoScreen XL YES/YAS assay. Chemosphere 112:362–369, PMID: 25048928, https://doi.org/10.1016/j.chemosphere.2014.04.080.
26. French National Assembly and Senate. 2010. LOI n° 2010-729 du 30 juin 2010 tendant à suspendre la commercialisation de tout conditionnement comportant du bisphénol A et destiné à recevoir des produits alimentaires.
27. Garcia-Hidalgo E, von Goetz N, Siegrist M, Hungerbühler K. 2017. Use-patterns of personal care and household cleaning products in Switzerland. Food Chem Toxicol 99:24–39, PMID: 27818321, https://doi.org/10.1016/j.fct.2016.10.030.
28. Gertz M, Houston JB, Galetin A. 2011. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos 39(9):1633, https://doi.org/10.1124/dmd.111. 039248.
29. Ginsberg G, Rice DC. 2009. Does rapid metabolism ensure negligible risk from bisphenol A? Environ Health Perspect 117(11):1639–1643, PMID: 20049111, https://doi.org/10.1289/ehp.0901010.
30. Goldinger DM, Demierre A-L, Zoller O, Rupp H, Reinhard H, Magnin R, et al. 2015. Endocrine activity of alternatives to BPA found in thermal paper in Switzerland. Regul Toxicol Pharmacol 71(3):453–462, PMID: 25579646, https://doi.org/10.1016/j. yrtph.2015.01.002.
31. Gramec Skledar D, Peterlin Mašič L. 2016. Bisphenol A and its analogs: do their metabolites have endocrine activity? Environ Toxicol Pharmacol 47:182–199, PMID: 27771500, https://doi.org/10.1016/j.etap.2016.09.014.
32. Hanioka N, Naito T, Narimatsu S. 2008. Human UDP-glucuronosyltransferase iso-forms involved in bisphenol A glucuronidation. Chemosphere 74(1):33–36, PMID: 18990428, https://doi.org/10.1016/j.chemosphere.2008.09.053.
33. Henderson JM, Heymsfield SB, Horowitz J, Kutner MH. 1981. Measurement of liver and spleen volume by computed tomography. Assessment of reproducibility and changes found following a selective distal splenorenal shunt. Radiology 141(2):525–527, PMID: 6974875, https://doi.org/10.1148/radiology. 141.2.6974875.
34. Herman RJ, Van Pham JD, Szakacs CBN. 1989. Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. Clin Pharmacol Ther 46(1):18–25, PMID: 2743706, https://doi.org/10.1038/clpt.1989.101.
35. Hewitt NJ, Bühring K-U, Dasenbrock J, Haunschild J, Ladstetter B, Utesch D. 2001. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab Dispos 29(7):1042–1050, PMID: 11408372.
36. Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B, et al. 1999. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos Biol Dispos 27(5):605–612, PMID: 10220490.
37. Hoffman FO, Hammonds JS. 1994. Propagation of uncertainty in risk assessments: the need to distinguish between uncertainty due to lack of knowledge and uncertainty due to variability. Risk Anal 14(5):707–712, PMID: 7800861, https://doi.org/10. 1111/j.1539-6924.1994.tb00281.x.
38. Hormann AM, Saal FS, vom Nagel SC, Stahlhut RW, Moyer CL, Ellersieck MR, et al. 2014. Holding thermal receipt paper and eating food after using hand sanitizer results in high serum bioactive and urine total levels of bisphenol A (BPA). PLOS ONE 9(10):e110509, PMID: 25337790, https://doi.org/10.1371/journal.pone. 0110509.
39. ICRP (International Commission on Radiological Protection). 2002. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age-and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP 32:1– 277, PMID: 14506981, https://doi.org/10.1016/S0146-6453(03)00002-2.
40. Ito K, Houston JB. 2005. Prediction of human drug clearance from in vitro and pre-clinical data using physiologically based and empirical approaches. Pharm Res 22(1):103–112, PMID: 15771236, https://doi.org/10.1007/s11095-004-9015-1.
41. Judy BM, Nagel SC, Thayer KA, Saal FSV, Welshons WV. 1999. Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice. Toxicol Ind Health 15(1-2):12–25, PMID: 10188188, https://doi.org/10.1177/074823379901500103.
42. Kitamura S, Suzuki T, Sanoh S, Kohta R, Jinno N, Sugihara K, et al. 2005. Comparative study of the endocrine-disrupting activity of bisphenol A and 19 related compounds. Toxicol Sci 84(2):249–259, PMID: 15635150, https://doi.org/10.1093/toxsci/kfi074.
43. Kortejärvi H, Urtti A, Yliperttula M. 2007. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci 30(2):155–166, PMID: 17187967, https://doi.org/10.1016/j. ejps.2006.10.011.
44. ' -Dihydroxy-2,2-diphenylpropane) using cryopreserved human hepatocytes. Drug Metab Dispos 35(10):1910–1915, PMID: 17646283, https://doi.org/10.1124/dmd.107. 014787.
45. Kurebayashi H, Okudaira K, Ohno Y. 2010. Species difference of metabolic clearance of bisphenol A using cryopreserved hepatocytes from rats, monkeys and humans. Toxicol Lett 198(2):210–215, PMID: 20599483, https://doi.org/10.1016/j. toxlet.2010.06.017.
46. Lebacq T. 2015. Anthropométrie (IMC, tour de taille et ratio tour de taille/taille). In: Enquête de consommation alimentaire 2014–2015. Rapport 1 [in French]. Brussels, Belgium:WIV-ISP.
47. Li M, Yang Y, Yang Y, Yin J, Zhang J, Feng Y, et al. 2013. Biotransformation of bisphenol AF to its major glucuronide metabolite reduces estrogenic activity. PLOS ONE 8(12):e83170, PMID: 24349450, https://doi.org/10.1371/journal.pone.0083170.
48. Liao C, Kannan K. 2013. Concentrations and profiles of bisphenol A and other bisphenol analogues in foodstuffs from the United States and their implications for human exposure. J Agric Food Chem 61(19):4655–4662, PMID: 23614805, https://doi.org/10.1021/jf400445n.
49. Liao C, Kannan K. 2011. Widespread occurrence of bisphenol A in paper and paper products: implications for human exposure. Environ Sci Technol 45(21):9372– 9379, PMID: 21939283, https://doi.org/10.1021/es202507f.
50. Liao C, Liu F, Guo Y, Moon H-B, Nakata H, Wu Q, et al. 2012. Occurrence of eight bisphenol analogues in indoor dust from the United States and several Asian countries: implications for human exposure. Environ Sci Technol 46(16):9138– 9145, PMID: 22784190, https://doi.org/10.1021/es302004w.
51. Liao C, Liu F, Kannan K. 2012. Bisphenol S, a new bisphenol analogue, in paper products and currency bills and its association with bisphenol A residues. Environ Sci Technol 46(12):6515–6522, PMID: 22591511, https://doi.org/10.1021/es300876n.
52. Lucier GW, Sonawane BR, McDaniel OS. 1977. Glucuronidation and deglucuronidation reactions in hepatic and extrahepatic tissues during perinatal development. Drug Metab Dispos 5(3):279–287, PMID: 17527.
53. Matthews JB, Twomey K, Zacharewski TR. 2001. In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A Glucuronide, with estrogen receptors α and β. Chem Res Toxicol 14(2):149–157, PMID: 11258963, https://doi.org/10.1021/tx0001833.
54. Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC. 2010. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38(12):2232–2238, PMID: 20736320, https://doi.org/10.1124/dmd.110.034819.
55. Mielke H, Gundert-Remy U. 2009. Bisphenol A levels in blood depend on age and exposure. Toxicol Lett 190(1):32–40, PMID: 19560527, https://doi.org/10.1016/j. toxlet.2009.06.861.
56. Mielke H, Partosch F, Gundert-Remy U. 2011. The contribution of dermal exposure to the internal exposure of bisphenol A in man. Toxicol Lett 204(2-3):190–198, PMID: 21571050, https://doi.org/10.1016/j.toxlet.2011.04.032.
57. Mørck TJ, Sorda G, Bechi N, Rasmussen BS, Nielsen JB, Ietta F, et al. 2010. Placental transport and in vitro effects of Bisphenol A. Reprod Toxicol 30(1):131–137, PMID: 20214975, https://doi.org/10.1016/j.reprotox.2010.02.007.
58. Motmans R. 2005. DINBelg. DINBelg 2005. http://www.dinbelg.be/[accessed 20 May 2017].
59. Nicklas TA, Baranowski T, Cullen KW, Berenson G. 2001. Eating patterns, dietary quality and obesity. J Am Coll Nutr 20(6):599–608, PMID: 11771675, https://doi.org/10.1080/07315724.2001.10719064.
60. Oberle RL, Chen T-S, Lloyd C, Barnett JL, Owyang C, Meyer J, et al. 1990. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 99(5):1275–1282, PMID: 2210236, https://doi.org/10. 1016/0016-5085(90)91150-5.
61. Oh J, Choi JW, Ahn Y-A, Kim S. 2018. Pharmacokinetics of bisphenol S in humans after single oral administration. Environ Int 112:127–133, PMID: 29272776, https://doi.org/10.1016/j.envint.2017.11.020.
62. Paigen K. 1989. Mammalian β-Glucuronidase: genetics, molecular biology, and cell biology. In: Progress in Nucleic Acid Research and Molecular Biology (W.E. Cohn and K. Moldave, eds). Vol. 37. New York, NY:Academic Press. 155–205.
63. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283(3):1552–1562, PMID: 9400033.
64. Pelkonen O, Kaltiala EH, Larmi TKI, Kärki NT. 1973. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin Pharmacol Ther 14(5):840–846, PMID: 4147122, https://doi.org/10.1002/cpt1973145840.
65. Reed MJ, Purohit A, Woo LWL, Newman SP, Potter BVL. 2005. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev 26(2):171–202, PMID: 15561802, https://doi.org/10.1210/er.2004-0003.
66. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. 2002. Enterohepatic circulation. Clin Pharmacokinet 41(10):751–790, PMID: 12162761, https://doi.org/10. 2165/00003088-200241100-00005.
67. Rocha BA, Azevedo LF, Gallimberti M, Campiglia AD, Barbosa F. 2015. High levels of bisphenol A and bisphenol S in Brazilian thermal paper receipts and estimation of daily exposure. J Toxicol Environ Health Part A 78(18):1181–1188, PMID: 26407846, https://doi.org/10.1080/15287394.2015.1083519.
68. Rochester JR, Bolden AL. 2015. Bisphenol S and F: a systematic review and comparison of the hormonal activity of bisphenol A substitutes. Environ Health Perspect 123(7):643–650, PMID: 25775505, https://doi.org/10.1289/ehp.1408989.
69. Rubin BS. 2011. Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127(1–2):27–34, PMID: 21605673, https://doi.org/10.1016/j.jsbmb.2011.05.002.
70. Schmitt W. 2008. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22(2):457–467, PMID: 17981004, https://doi.org/10. 1016/j.tiv.2007.09.010.
71. Schoene B, Fleischmann RA, Remmer H, Oldershausen HF. v. 1972. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol 4(2):65–73, PMID: 4144102, https://doi.org/10.1007/BF00562499.
72. Schönfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I. 2002. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect 110(11):A703–A707, PMID: 12417499.
73. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503–512, PMID: 7310648, https://doi.org/10.1007/BF01060893.
74. Skledar DG, Schmidt J, Fic A, Klopčcičc I, Trontelj J, Dolenc MS, et al. 2016. Influence of metabolism on endocrine activities of bisphenol S. Chemosphere 157:152–159, PMID: 27213244, https://doi.org/10.1016/j.chemosphere.2016.05. 027.
75. Skledar DG, Troberg J, Lavdas J, Mašičc LP, Finel M. 2015. Differences in the glucuronidation of bisphenols F and S between two homologous human UGT enzymes, 1A9 and 1A10. Xenobiotica 45(6):511–519, PMID: 25547628, https://doi.org/10.3109/00498254.2014.999140.
76. Snyder RW, Maness SC, Gaido KW, Welsch F, Sumner SCJ, Fennell TR. 2000. Metabolism and disposition of bisphenol A in female rats. Toxicol Appl Pharmacol 168(3):225–234, PMID: 11042095, https://doi.org/10.1006/taap.2000. 9051.
77. SPARC. 2011. pKa/property server. http://archemcalc.com/sparc/[accessed 5 July 2017].
78. Squara P, Denjean D, Estagnasie P, Brusset A, Dib JC, Dubois C. 2007. Noninvasive cardiac output monitoring (NICOM): a clinical validation. Intensive Care Med 33(7):1191–1194, PMID: 17458538, https://doi.org/10.1007/s00134-007-0640-0.
79. Stossi F, Bolt MJ, Ashcroft FJ, Lamerdin JE, Melnick JS, Powell RT, et al. 2014. Defining estrogenic mechanisms of bisphenol A analogs through high throughput microscopy-based contextual assays. Chem Biol 21(6):743–753, PMID: 24856822, https://doi.org/10.1016/j.chembiol.2014.03.013.
80. Street CM, Zhu Z, Finel M, Court MH. 2017. Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms. Xenobiotica 47(1):1–10, PMID: 26999266, https://doi.org/10.3109/00498254.2016.1156784.
81. Teeguarden JG, Twaddle NC, Churchwell MI, Yang X, Fisher JW, Seryak LM, et al. 2015. 24-hour human urine and serum profiles of bisphenol A: evidence against sublingual absorption following ingestion in soup. Toxicol Appl Pharmacol 288(2):131–142, PMID: 25620055, https://doi.org/10.1016/j.taap.2015.01.009.
82. Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, Barton HA. 2005. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. Toxicol Sci 85(2):823–838, PMID: 15746009, https://doi.org/10.1093/toxsci/kfi135.
83. Thayer KA, Doerge DR, Hunt D, Schurman SH, Twaddle NC, Churchwell MI, et al. 2015. Pharmacokinetics of bisphenol A in humans following a single oral administration. Environ Int 83:107–115, PMID: 26115537, https://doi.org/10.1016/j. envint.2015.06.008.
84. Thayer KA, Taylor KW, Garantziotis S, Schurman SH, Kissling GE, Hunt D, et al. 2016. Bisphenol A, bisphenol S, and 4-Hydroxyphenyl 4-Isoprooxyphenylsulfone (BPSIP) in urine and blood of cashiers. Environ Health Perspect 124(4):437–444., PMID: 26309242, https://doi.org/10.1289/ehp.1409427.
85. Thomopoulos NT. 2013. Essentials of Monte Carlo Simulation. Springer:New York.
86. Tobacman JK, Hinkhouse M, Khalkhali-Ellis Z. 2002. Steroid sulfatase activity and expression in mammary myoepithelial cells. J Steroid Biochem Mol Biol 81(1):65–68, PMID: 12127043, https://doi.org/10.1016/S0960-0760(02) 00048-1.
87. Toner F, Allan G, Beyer D, Dimond SS, Kocabas NA. 2016. The in vitro percutaneous absorption and metabolism of Bisphenol A (BPA) through fresh human skin. Toxicol Lett 258 (suppl):S180. PMID: 29154941, https://doi.org/10.1016/j. toxlet.2016.06.1669.
88. Trdan Lušin T, Roškar R, Mrhar A. 2012. Evaluation of bisphenol A glucuronidation according to UGT1A1*28 polymorphism by a new LC–MS/MS assay. Toxicology 292(1):33–41, PMID: 22154984, https://doi.org/10.1016/j.tox.2011.11.015.
89. Tsukioka T, Terasawa J, Sato S, Hatayama Y, Makino T, Nakazawa H. 2004. Development of analytical method for determining trace amounts of BPA in urine samples and estimation of exposure to BPA. J Environ Chem 14(1):57–63, https://doi.org/10.5985/jec.14.57.
90. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. 2007. Human exposure to bisphenol A (BPA). Reprod Toxicol 24(2):139–177, https://doi.org/10. 1016/j.reprotox.2007.07.010.
91. Vogt W. 2014. Evaluation and optimisation of current milrinone prescribing for the treatment and prevention of low cardiac output syndrome in paediatric patients after open heart surgery using a physiology-based pharmacokinetic drug–disease model. Clin Pharmacokinet 53(1):51–72, PMID: 23839530, https://doi.org/10.1007/s40262-013-0096-z.
92. Völkel W, Colnot T, Csanády GA, Filser JG, Dekant W. 2002. Metabolism and kinetics of Bisphenol A in humans at low doses following oral administration. Chem Res Toxicol 15(10):1281–1287, PMID: 12387626, https://doi.org/10.1021/tx025548t.
93. von Goetz N, Pirow R, Hart A, Bradley E, Poças F, Arcella D, et al. 2017. Including non-dietary sources into an exposure assessment of the European Food Safety Authority: the challenge of multi-sector chemicals such as Bisphenol A. Regul Toxicol Pharmacol 85:70–78, PMID: 28185845, https://doi.org/10.1016/j.yrtph. 2017.02.004.
94. Walsh DE, Dockery P, Doolan CM. 2005. Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca2+]i in human breast cancer cells. Mol Cell Endocrinol 230(1–2):23–30, https://doi.org/10.1016/j.mce.2004.11.006.
95. Yang X, Doerge DR, Teeguarden JG, Fisher JW. 2015. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. Toxicol Appl Pharmacol 289(3):442–456, PMID: 26522835, https://doi.org/10.1016/j.taap.2015.10.016.
96. Yu LX, Crison JR, Amidon GL. 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140(1):111–118, https://doi.org/10.1016/0378-5173(96)04592-9.
97. Zalko D, Jacques C, Duplan H, Bruel S, Perdu E. 2011. Viable skin efficiently absorbs and metabolizes bisphenol A. Chemosphere 82(3):424–430, PMID: 21030062, https://doi.org/10.1016/j.chemosphere.2010.09.058.
98. Zhang H, Zhang Y. 2006. Convenient nonlinear model for predicting the tissue/blood partition coefficients of seven human tissues of neutral, acidic, and basic structurally diverse compounds. J Med Chem 49(19):5815–5829, PMID: 16970406, https://doi.org/10.1021/jm051162e.
99. Zhang Q-Y, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. 1999. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27(7):804–809, PMID: 10383924.